This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Savient Pharmaceuticals: Premarket Trading

(Premarket story updated with Savient Pharmaceuticals news and share price information.)

NEW YORK ( TheStreet) -- Savient Pharmaceuticals (SVNT - Get Report) said that president Paul Hamelin will continue to lead the company until it finds a new CEO.

Shares of the company are down 1.02%, or 12 cents, to $11.65 in premarket trading.

Capital Markets analyst Robert Norfleet upgraded engineering and construction firm KBR (KBR - Get Report) to a buy rating from a hold, saying rising commodity prices will likely boost demand for its services. He set a $37 price target on the shares.

KBR shares are up 2.88%, or 89 cents, to $31.79 in premarket trading.

Biotechnology company MannKind (MNKD) has announced that the U.S. Food and Drug Administration is delaying a decision on the company's diabetes drug, Afrezza. MannKind said the FDA needs about four more weeks to complete its evaluation of the inhaled insulin drug.

MannKind stock is up 0.12%, or 1 cent, to $8.24 in premarket trading.

Equities research analysts at Davenport raised their 2011 and 2012 earnings estimates for Alcoa (AA - Get Report) on Monday to $1.12 and $1.40, respectively, from $1.05 and $1.32 on higher aluminum prices.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SVNT $0.00 0.00%
AA $12.88 -0.69%
KBR $14.41 0.21%
MNKD $5.11 0.20%
AAPL $124.24 0.70%


DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs